This $323,001 Project Grant awarded by the National Institute of Neurological Disorders and Stroke (NINDS) under the Extramural Research Programs in the Neurosciences and Neurological Disorders (CFDA 93.853) program supports the development of Axonis Therapeutics' proprietary oral KCC2 potentiator drug, AXN-027, as a novel anti-epileptic therapy for mesial temporal lobe epilepsy (MTLE).
The funding will enable preclinical testing of AXN-027 in a well-characterized mouse model of MTLE to investigate the drug's anti-seizure efficacy. Axonis Therapeutics, a biotechnology company focused on neurological disorders, has conducted previous federally-funded research on KCC2 potentiators as potential treatments for conditions like spinal cord injury, diabetic neuropathy, and glaucoma. This Project Grant award represents continued support from NINDS to advance Axonis' development of a first-in-class KCC2-potentiating anti-epileptic drug to address the significant unmet need for new treatment options for drug-resistant MTLE patients.
Generated 1/28/25, 8:14 AM